Tafamidis
Composition
Contains Tafamidis meglumine or tafamidis free acid, typically 20 mg or 61 mg capsules/tablets.
Indications
Used to treat transthyretin amyloid cardiomyopathy (ATTR-CM) to slow disease progression and improve quality of life.
Side effects
Generally well tolerated; possible headache, urinary tract infections, diarrhea.
Precautions
Monitor liver function; use cautiously in severe hepatic impairment.
Contraindications
Hypersensitivity to Tafamidis or any component of the formulation.
Dosage and administration
Usually 61 mg once daily (tafamidis free acid formulation) or 20 mg twice daily (megumine formulation).
Countries
Available Forms
Oral capsules/tablets.